SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): March 8, 2006
NEUROCRINE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
Delaware
(State or other
jurisdiction of
incorporation or
organization)
|
|
0-22705
(Commission File
Number)
|
|
33-0525145
(IRS Employer Identification
No.) |
| |
|
|
| 12790 El Camino Real
|
|
92130 |
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (858) 617-7600
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 |
| |
| o |
|
CFR 240.14d-2 (b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 |
| |
| o |
|
CFR 240.13e-4 (c)) |
TABLE OF CONTENTS
Item
8.01 Other Events
On March 8, 2006, Neurocrine Biosciences, Inc. issued a press release to provide an update on
the Company’s drug development pipeline, including the discontinuing of the development of the
APL-MS program. The full text of the press release issued in connection with the announcement is
filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
99.1 Press Release dated March 8, 2006